The stock last traded at $32.58 which is quite a bit higher than $29.57, the stock’s 50 day moving average and which is a tad under the 200 day moving average of $35.29. The 50 day moving average was up $3.01 and the 200 day average went down $-2.71 or -7.69%. Theravance Biopharma, Inc. – Or shares had a trading volume of 100K on Wednesday. Shares saw a steep decrease in trading volume of 48.10% under the normal average daily volume.
Investors are more bearish on the company lately if you take note of the change in short interest. The firm saw a rise in short interest between August 15, 2017 and August 31, 2017 of 0.57%. Short interest grew 35,802 over that timeframe. With short interest at 6,316,643 and short average daily volume at 263,037, days to cover is 24.0 and the percentage of shorted shares was 0.12% on August 31.
Theravance Biopharma, Inc. – Or (NASDAQ:TBPH) has been the object of insider buying activity recently. CEO Rick E. Winningham disclosed the purchase of 10,000 shares. The shares were purchased at an average price of $24.50. Winningham now owns $21,226,237 of the stock according to the SEC filing. Henrietta Fore, Director disclosed the purchase of 6,000 shares of TBPH stock. The shares were bought on August 11th for an average price of $23.99. The Director now owns $575,760 of the stock per the Form 4 SEC filing.
These funds have shifted positions in (TBPH). As of the end of the quarter Woodford Investment Management Ltd had bought 3,881,543 shares growing its stake by 56.9%. The value of the investment in (TBPH) increased from $128,303,000 to $426,531,000 a change of 232.4% quarter to quarter. Pacad Investment Ltd. downsized its investment by shedding 10,900 shares a decrease of 82.0%. Pacad Investment Ltd. now holds 2,400 shares worth $96,000. The total value of its holdings decreased 80.4%.
Ubs Group Ag bolstered its ownership by buying 1,009 shares an increase of 504.5% as of 06/30/2017. Ubs Group Ag claims 1,209 shares with a value of $48,000. The value of the position overall is up by 585.7%. Hillhouse Capital Management, Ltd. reduced its holdings by selling 181,400 shares a decrease of 59.6% in the quarter. Hillhouse Capital Management, Ltd. now controls 122,856 shares valued at $4,895,000. The value of the position overall is down by 56.3%.
Equity analyst Evercore ISI Group initiated coverage on the stock by announcing an initial rating of “Outperform”. On June 16 analysts at Cantor Fitzgerald starting coverage on the stock with a rating of “Overweight”.
In the latest earnings report the EPS was $-4.66 and is estimated to be $-4.85 for the current year with 53,829,000 shares outstanding. Next quarter’s EPS is estimated at $-1.19 and the next full year EPS is projected to be $-4.21.
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is involved in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Business’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Business’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Business’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy..